Leading cancer care from prevention to survivorship with advanced research, individualized treatment, and dedicated care coordination support.
Joined November 2009
- Tweets 7,138
- Following 2,417
- Followers 33,307
- Likes 2,592
2,850 Photos and videos
Pinned Tweet
7 Jun 2025
We're honored that @Newsweek has recognized Siteman as the No. 1 cancer center in Missouri and Illinois — and among the best of the best nationally.
siteman.wustl.edu/newsweek-n…
1
9
29
3,488
Smoking duration v. pack-years: After analyzing data from nearly 1M vets, @washumedicine's Brendan Heiden, MD, suggests duration metrics may better identify individuals at higher risk for lung cancer: ascopost.com/videos/asco-202… #ASCO26
109
As #ASCO26 wraps up, take a look at the @washumedicine research presented by Siteman members, including breakthroughs in head and neck, endometrial cancers and more: siteman.wustl.edu/siteman-ca…
1
2
159
New from #ASCO26: @washumedicine’s Brendan Heiden, MD, suggests a paradigm shift in lung cancer screening: changing the metric from tobacco-pack years to tobacco smoking duration. Learn more: dailynews.ascopubs.org/do/ne…
122
Food insecurity and financial stress can negatively impact the biology of breast cancer and the outcomes of patients, @washumedicine medical oncologist Emily Podany, MD, of Siteman Cancer Center, tells us.
Watch her discuss these findings, which she presented at #ASCO26.
5
206
Siteman Cancer Center retweeted
From Bench-to-Beside! WashU Hematology is excited to bring this research from the Oh Lab (@mpndoc) all the way to a clinical trial offered at @SitemanCenter. #TranslationalResearch
Congrats Amy Zhou, MD @WashUHematology on launching a new clinical trial of PMD-026 for chronic myelofibrosis patients who failed or are intolerant to JAK inhibitors—built on discoveries from Dr. Stephen Oh’s lab in collab with Phoenix Molecular Designs. bit.ly/4ebpOW5
ALT Phoenix Molecular Designs Expands PMD-026 into Second Clinical Indication with Myelofibrosis Trial at WashU Medicine
2
5
763
The KEYNOTE-689 trial of pembro in locally advanced H&N cancer has yielded practice-changing results. Looking ahead, data from the study could help trial leaders, including Douglas Adkins, MD, develop more strategies to enhance survivability. #ASCO26
3
221
With ongoing support, the best minds in cancer research can meet the challenge for the greater good of patients, said @washumedicine surgeon Sidharth Puram, MD, PhD, FACS, co-director of the Head & Neck Tumor Center at Siteman Cancer Center. #ASCO26.
1
138
There’s new hope for patients diagnosed with neuroendocrine tumors. @washumedicine medical oncologist Nikolaos A. Trikalinos, MD, MS, of Siteman Cancer Center, discusses the advances, which he presented at #ASCO26.
171
Great article, @TargetedOnc!
Kudos to Dr. McCourt, RUBY co-author, on her interview below and lead author and @asco presenter Dr. Powell on this incredible clinical trial striving towards extending the lives of those with advanced or recurrent endometrial cancer.
🎥 WATCH: At #SGOAM26, Matthew Powell, MD (@washumedicine) discussed long-term overall survival results with dostarlimab plus chemo in dMMR #EndometrialCancer patients from the RUBY trial. #GynOnc
targetedonc.com/view/dostarl…
1
5
477
#ASCO26: Time is running out! Meet Chair and Moderator Cynthia Ma, MD, PhD, a @washumedicine medical oncologist, as @ASCO’s Rapid Oral Abstract on Developmental Therapeutics winds down at 11:15 a.m. CT today, room E451.
For more, follow us and visit siteman.wustl.edu/asco/
1
201
Siteman Cancer Center retweeted
The #1 abstract on my radar at #ASCO26 was RASolute 302 (LBA5). RASolute 302 is a phase 3, international, open-label, randomized trial ofdaraxonrasib 300 mg daily vs investigator's choice chemo as 2nd line Rx in pts w/ metastatic pancreatic ductal adenocarcinoma (mPDAC).
1
2
4
361
#ASCO26: Kian-Huat Lim, MD, PhD, a leader of Siteman’s pancreatic SPORE, is proud to have been a clinical site for the RASolute 302 study that underlies promising pancreatic cancer findings, also discussed at this year’s @ASCO.
Learn more: siteman.wustl.edu/research/s…
1
155
Closing out #ASCO26 strong. Here is our @washumedicine presenter for the day from Siteman Cancer Center.
1
128
Siteman Cancer Center retweeted
awesome to see Dr Reimers from @washumedicine @WashUOncology @SitemanCenter give expert review at #ASCO26
1
2
7
415
Siteman Cancer Center retweeted
Jun 1
Behind the scenes of #ASCO26 Day 3, where this morning, we brought together a panel of #Glioma key opinion leaders to discuss the biggest abstracts and field-changing data coming out of this year's conference.
Moderated by Dr. Rimas Lukas (@NMNeurology), alongside:
Dr. Omar Butt (@SitemanCenter)
Dr. Heather Leeper (@UChicago_Neuro)
Dr. Nicolas Gonzalez Castro (@DanaFarber)
2
3
336
#ASCO26: Going on now! @washumedicine Pediatric Hematologist Amy Armstrong, MD, presents poster #359, Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma, at @ASCO until 4:30 p.m. CT in Hall A!
3
171
#ASCO26: Large crowd for @ASCO’s Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic
Cancers session featuring @washumedicine oncologists Drs. Govindan and Heiden.
Live now through 4:15 p.m. here at Hall D1 Streaming!
2
163
New #ASCO26 research links food deserts to aggressive breast cancer mutations and shorter survival. @Cure_Today spoke with @washumedicine's Dr. Emily Podany of Siteman on why screening for non-medical factors matters. curetoday.com/view/food-dese…
1
120